The electrophysiologic effects of oral encainide (75 to 150 mg daily) were evaluated in 14 patients (6 male and 8 female, aged 49 + 9 years) with atrioventricular (AV) node reentrant tachycardia of the slow-fast type. The patients were studied in control conditions and after 2 to 12 days of treatment.
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The electrophysiologic effects of oral encainide (75 to 150 mg daily) were evaluated in 14 patients (6 male and 8 female, aged 49 + 9 years) with atrioventricular (AV) node reentrant tachycardia of the slow-fast type. The patients were studied in control conditions and after 2 to 12 days of treatment.
mean plasma concentrations of encainide and its metabolites 0-demethyl-encainide and 3.methoxy-O-demethyl-encainide measured in 13 patients during the repeat study were 161 2 304, 128 -C 100 and 95 f 85 ng/ml, respectively; three poor metabolizers who presented a high concentration of the parent compound were observed in this series. Encainide increased the AH interval from 67 f 10 to 82 f 23 ms (p < 0.02). Anterograde Wenckebach cycle length was increased in three patients, reduced in four, unchanged in one; it was not measurable in the remaining patients because tachycardia was induced. Retrograde Wenckebach periodicity increased from 307 f 71 to 401 f 92 ms (p < 0.005) in all nine patients in whom it was measurable; complete retrograde block was observed in one patient. At the control study, tachycardia was induced in ail patients, with a mean cycle length of 341 f 50 ms; after encainide, tachycardia was inducible in only 1 patient, with an increase in cycle length from 270 to 320 ms; in the other patients, tachycardia was not inducible because of a lack of retrograde (11 patients) or anterograde (2 patients) conduction. The All patients were discharged on encainide at a mean daily dose of 112 f 39 mg. One patient dropped out of the study 1 month later because of neurologic side effects (blurred vision and vertigo). During a mean follow-up period of 24 f 11 months, nine patients are completely free of attacks, three patients had only one recurrence and one patient had a marked reduction of attacks; no one complained of side effects.
Encainide appears to be highly effective in preventing AV node reentrant tachycardia, mainly by depressing conduction in the retrograde limb of the reentrant circuit. The drug demonstrates long-term clinical efficacy and does not induce any significant side effect at the doses used in this trial.
( J Am Co11 Cardiol1989; 14:992-8) Encainide is a class IC antiarrhythmic drug (1) that has been recently introduced in clinical use for treatment of ventricular arrhythmias. As an investigational drug, it was also shown to be highly effective in the treatment of supraventricular arrhythmias, particularly when involving an accessory atrioventricular (AV) pathway (2-5). In contrast, little information is yet available on its usefulness in paroxysmal AV node reentrant tachycardia, in which the reentrant loop is confined to the AV node and utilizes a "slow" pathway in the anterograde direction and a "fast" pathway in the retrograde direction. Because encainide has been demonstrated to depress conduction both in fast sodium channel-dependent fibers as well as in slow channel-dependent fibers, particularly when given orally (5-7), it was postulated that the drug should be effective in AV node reentrant tachycardia in which the mechanism appears to involve both types of fibers. 63 years (mean t S.D. 49 lr 9). During sinus rhythm, only one patient (Case 12) showed electrocardiographic (ECG) evidence of the Wolff-Parkinson-White pattern, but this patient was included in this group because the accessory pathway was shown not to be involved in the reentrant mechanism. All patients underwent clinical, radiographic and echocardiographic examinations that revealed cardiac abnormalities in only two patients (Cases 3 and 6) who had signs of previous myocardial infarction. These two patients complained of angina pectoris during tachycardia; in Case 6, coronary artery bypass operation was performed 1 year before entry to this study, which eliminated the angina, but did not influence the number of paroxysms of tachycardia.
No patient had evidence of renal or hepatic dysfunction. Basal electrophysiologic study. All patients enrolled gave their informed written consent; the study protocol was approved by the institution's Ethical Committee on Human Research. The electrophysiologic studies were performed in the postabsorptive and nonsedated state. Before the studies. any previous drug treatment was stopped for at least 5 elimination half-lives. For the control study, four multipolar electrode catheters were introduced percutaneously under local anesthesia and positioned under fluoroscopic control in the high lateral right atrium. left atrium (through the coronary sinus), apex of the right ventricle and His bundle region, and were used for recording and stimulation. Four surface ECG leads (I, III, V, and V,) and all intracardiac electrograms were displayed simultaneously on a multichannel oscilloscope and recorded at paper speeds of 50 to 100 mm/s. Electrical stimulation was provided with a programmable stimulator (Cardiovascular Instruments model 4279).
using rectangular impulses with a duration of 2 ms at twice diastolic threshold.
The stimulation protocol included: incremental atria1 pacing, single atria1 premature beats during atria1 pacing, incremental ventricular pacing, single ventricular premature beats during ventricular pacing and atria1 or ventricular extrastimulus and overdrive pacing, or both, during tachycardia. Previously reported conventional criteria (8) were utilized to identify the exact mechanism of tachycardia, particularly to exclude the participation of an accessory AV pathway as the retrograde limb of the circuit.
Encainide study. At the end of the control electrophysiologic study, the first seven patients were given oral encainide in a dosage of 50 mg every 8 h. After observing the favorable results obtained with this dosage, it was decided to verify in the remaining patients (Cases 8 to 14) whether the same effectiveness could be achieved with a dose of 25 mg every 8 h. After 2 to 12 days (mean 5 + 3) of this regimen, electrophysiologic study was repeated 1 to 2 h after an oral dose, using the same technique and the same stimulation protocol (the catheter in the coronary sinus was not utilized in the repeat study). A heparinized blood sample for evaluation of drug concentration was drawn at the beginning of stimulation; concentrations of encainide and its active metabolites 0-demethyl-encainide and 3-methoxy-O-demethylencainide were determined by high performance liquid chromatography (9). Follow-up. All patients were discharged on encainide therapy at the daily dose tested during electrophysiologic study and independently of its results. The patients were observed monthly for the initial 3 months and at 3 month 14, No. 4 October 1989992-8 intervals thereafter; they were carefully questioned about symptoms and side effects and underwent physical examination, 12 lead ECG, standard blood chemistry screening and ambulatory ECG recording.
Statistical analysis. Results are presented as the mean value k SD. Student's t test for paired data was used, when indicated, to determine probable differences; a p value CO.05 was regarded as significant.
Results
Electrophysiologic effects (Table 2) . No patient reported any side effects while in the hospital; all the studies were carried out without complications. The electrophysiologic data in Table 2 are considered separately according to the dose used (75 versus 150 mg daily). The findings are in accordance with those previously reported (2-7) and confirm a modest increase in both conduction and refractoriness variables induced by the drug. It is noteworthy that in this group of patients with AV node reentrant tachycardia, anterograde conduction velocity through the AV node, as measured by AH interval duration, is decreased by the drug at both doses. In the entire group of patients, AH interval increased from 67 + 10 to 82 k 23 ms (mean 15 + 18; range 0 to 50) (p < 0.02). The drug also induced only a slight increase in ECG intervals; in particular, QRS duration, the increase of which is usually considered a measure of toxic effects, did not increase significantly in this group of patients, probably because of the mean low dosage employed.
Drug effects on tachycardia (Table 3) . Because anterograde and retrograde conduction and refractoriness of the AV node are involved in the mechanism of induction and I50  cl80  150  260  150  320  150  250  150  <220  150  230  150  <240  75  <260  75  290  75  <230  75  <220  75  <260  75  270  75  180   ~250  360  ~270  <210  ~230  260   260  310  <240  <240  ~270  270  <210   ~270  490  360  360  340  580  ~230  Block  270  400  230  Block  <260  <290  400  380  460  500  <240  ~230  NA  320  NA  NA  1200  ~260  250  240  240  330  <280  ~250  260  300  240  310  1200  340  350  300  250  380  <240  <250  NA  400  270  320  NA  NA  NA  420  NA  NA  260  1250  280  310  320  410  <230  220  NA  380  290  340  1230  ~290  NA  400  NA  350  <230  <230  360  350  350 All values are expressed in milliseconds. AVN = atrioventricular node; AVNRT = atrioventricular node reciprocating tachycardia; C = control study; E = encainide study; ERP = effective refractory period: NA = not available; NI = not induced; VACS = ventriculoatrial conduction system. 
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changes induced by oral encainide on these variables were analyzed. Both anterograde AV node and retrograde conduction system effective refractory periods could not always be measured because they were limited by atria1 and ventricular refractoriness, so statistical analysis of the data was not performed. By considering only the patients whose data could be compared, at least qualitatively, the drug increased anterograde AV node refractoriness in four of seven patients and retrograde conduction system effective refractory period in five of six patients; in one of the latter patients, retrograde conduction block was observed at the repeat study. The anterograde Wenckebach cycle length was not measurable in six patients at the control study because of the induction of tachycardia. In the remaining patients, this variable was either increased (three patients) or reduced (four patients) and in one patient it was unchanged. The retrograde Wenckebach periodicity was not identified in 3 of 13 patients (in Case 9, ventricular stimulation was not performed) because of tachycardia onset in the control study. In all other patients, this variable increased by 40 to 240 ms; the mean value increased significantly from 307 2 71 to 401 t 92 ms (p < 0.005). In all patients, tachycardia was repeatedly induced with electrical stimulation during control study. A clear dual AV node pathway conduction pattern, identified by a discontinuous response of AV node conduction time to progressively premature stimuli, was demonstrated in eight patients. A paroxysm of tachycardia started every time anterograde conduction jumped through the slower pathway. Tachycardia mean cycle length was 341 + 50 ms. In the repeat study on drug therapy, tachycardia could not be induced with any technique of atria1 and ventricular stimulation except in one patient (Case 4), in whom tachycardia cycle length increased from 270 to 320 ms. In 11 patients, tachycardia was not inducible with atria1 premature stimulation because of the lack of conduction in the retrograde limb of the circuit (Fig.  I) , whereas in the remaining 2 patients one or two echo beats were not followed by anterograde conduction. In Case 2. complete retrograde dissociation was demonstrated in the repeat study.
Drug plasma levels (Table 4 ). In 13 of the 14 patients, the drug concentrations of encainide and of its two metabolites (0-demethyl-encainide and 3-methoxy-O-demethylencainide) at the time of stimulation during repeat study were available. The mean values were 161 L 304, 128 * 100 and 95 t 85 ngiml, respectively. Three of these patients (Cases 6, 8 and 13) considered "poor metabolizers" are included in this series; encainide plasma concentration was particularly high in these three patients (990, 226 and 638 ng/ml, respec- Follow-up. All patients were discharged on encainide therapy at the same dose tested while they were in the hospital, including Patient 4, who was the only patient to have the tachycardia induced during electrophysiologic study after administration of encainide. The mean maintenance dose was 112 ? 39 mg daily. Patient 8, who was one of the poor metabolizers of this series, complained of blurred vision and mild vertigo a few days after discharge; she refused a dose reduction and was definitively dropped from the study 1 month later. At that time, no information was yet available about her drug and metabolite plasma concentrations. The remaining 13 patients were followed up for 10 to 44 months (mean 24 ? 11); none complained of any side effects during the follow-up period. All but four patients were completely free of attacks; Patients 3, 6 and 7 had only one episode each during the prolonged period of treatment (26, 18 and 16 months, respectively). The paroxysms were better tolerated, of shorter duration and never required hospitalization. Finally, only Patient 2, who had a history characterized by a mean of one episode daily despite previous treatments, continued to report a mean of one episode monthly, interrupted with vagal stimulation maneuvers.
Discussion
Effects of encainide on tachycardia. Repeat electrophysiologic studies during treatment have been utilized for many years in patients with various types of tachycardias to predict the clinical efficacy of antiarrhythmic drugs. In patients with paroxysmal AV node reentrant tachycardia, previous studies have reported on the antiarrhythmic activity of several drugs, such as propranolol (lo), ouabain (1 l), verapamil (12) , procainamide (13) , quinidine (14) , disopyramide (15) and flecainide (16) .
Paroxysmal AV node reentrant tachycardia is sustained by a reentrant mechanism confined to the AV node region. The anterograde limb of the circuit is composed of the AV node (or part of it) (that is, by slow conducting fibers particularly sensitive to calcium channel antagonists, digitalis or beta-adrenergic blockers). In contrast, the retrograde limb is composed of a nodal (or paranodal of the James fibers type) structure characterized by fast conduction. This structure is, thus, sensitive to antiarrhythmic agents of the class I or III type.
Drugs further decreasing the slow anterograde nodal conduction are commonly utilized to interrupt a paroxysm of AV node reentrant tachycardia. Paradoxically, such drugs not only are often ineffective in preventing recurrences of tachycardia, but also may increase recurrences because slower conduction of premature atria1 beats may favor reentry of the impulse to the atria. The ideal antiarrhythmic agent to prevent AV node reentrant tachycardia should, therefore, exert a double activity. On the one hand, it should depress slow channel-dependent anterograde AV node conduction to decrease the rate and possibly interrupt the tachycardia. At the same time, the drug should also decrease conduction in the fast sodium channel-dependent fibers involved in the retrograde limb of the loop to prevent reentry of slowly conducted beats. Encainide seems to have both these properties, as amply demonstrated in previously reported studies (2-6). The drug was demonstrated to be very active in preventing induction of supraventricular tachycardias sustained by reentry involving an accessory AV pathway in retrograde direction (2-5). Only sporadically has the drug activity been evaluated in patients with AV node reentrant tachycardia. Miles et al. (17) demonstrated antiarrhythmic efficacy of encainide in two of three patients with this type of tachycardia.
In our series, encainide demonstrated excellent activity in preventing electrically inducible AV node reentrant tachycardia. In all but one patient, tachycardia could no longer be induced on treatment, even at the lower dose tested (75 mg daily). It is noteworthy that in 10 of 13 patients, tachycardia was not induced because of the lack of conduction in the retrograde pathway. The greater activity of the drug on the fast sodium channel-dependent structure was also demonstrated by the overall greater effects on the shortest cycle length with 1: 1 conduction in retrograde direction compared with the anterograde direction, which is more widely influenced by autonomic tone changes. This prevalent effect on retrograde fast pathway conduction was also demonstrated in patients treated with procainamide (13) , quinidine (14) , disopyramide (15) and flecainide (16) .
Electrophysiologic effects. The effects of encainide on the principal electrophysiologic and ECG variables observed in this study are similar to those previously reported (6). It should be noted that a lesser increase of these variables was observed in this study (Table 2) because of the lower doses utilized (75 and 150 mg daily versus a mean of 242 mg daily in the study performed by Jackman et al. [61) . The most impressive effect of encainide was observed on retrograde conduction, which was depressed in all patients. In the eight patients in whom anterograde and retrograde Wenckebach cycle lengths could be compared. the drug exerted a greater effect on retrograde conduction. In contrast, no significant difference was evident between the effects of the lower compared with the higher dose.
Encainide plasma concentrations. In our group of patients, plasma concentrations of encainide and its metabolites showed great interindividual variability. Moreover. no clear correlation was evident between plasma levels of the drug or its metabolites and electrophysiologic activity. It is believed that approximately 10% of the population is genetically unable to metabolize the drug (18) . Three poor metabolizers were present in our series; plasma concentrations of encainide at the time of study were particularly high in these patients, but no clear difference was demonstrated in the electrophysiologic behavior of these patients compared with the others. It is of interest that one of the poor metabolizers was the only patient to develop mild side effects a few days after discharge when blood concentration of encainide was much higher than the mean.
Clinical effects. The clinical antiarrhythmic efficacy of encainide was widely demonstrated during a prolonged follow-up period. With the exception of one patient, all were virtually completely protected by this treatment, even at a mean maintenance dose that was particularly low. In a previous series of patients with the Wolff-Parkinson-White syndrome (5). the mean maintenance dose able to prevent recurrences of tachyarrhythmias in most of the patients was also very low (127 mg daily), much lower than the doses reported by others in patients with supraventricular tachycardias: 197 mg daily (2) and 175 mg daily (3). This finding confirms that, at least in paroxysmal supraventricular tachycardia. encainide is highly effective at doses of ~150 mg daily. In this way, the incidence of side effects is very low.
The very low number of recurrences observed during treatment in both laboratory and clinical settings makes prediction of clinical outcome on the basis of laboratory tests very difficult. It is impossible to evaluate sensitivity and specificity of the laboratory test. It also must be kept in mind that the drug suppresses ectopic activity, the trigger in most supraventricular tachycardias, and this may be another mechanism of prevention of clinical tachycardias. In any case, it should be emphasized that the only patient who had recurrences at the repeat electrophysiologic study was completely free of attacks during the follow-up period, and the only patient who had more than one recurrence during follow-up period had the highest number of attacks and previous treatment failures by history.
Conclusions. The present study demonstrates that oral encainide. even at a low dose of 75 mg daily, prevents laboratory induction of AV node reentrant tachycardia mainly by depressing conduction over the retrograde limb of the reentrant circuit. Drug efficacy was confirmed during clinical use by suppressing recurrences in the great majority of patients treated. When utilized at a low dose, the drug is safe and well tolerated in most patients.
